The capacity to make with biology: fermentation, cell and gene production platforms, vaccine and biologics manufacture, and the bioprocess technology that turns biological designs into supply.
The Capability Development Index tracks the events that move a capability — operational use, technical breakthroughs, procurement decisions and the industrial base behind them — and places each on the record with the date it happened.
Recent developments cover the current period. Historical developments are the inflection points that produced Biomanufacturing as it stands today.
Residues in pottery from the Yellow River valley show a drink made from rice, honey and fruit, evidence that using living organisms to manufacture a consumable product is a Neolithic technology.
Using the mould Aspergillus niger, the process ended reliance on imported Italian citrus for citric acid and became the model for large-scale industrial fermentation of organic acids and, later, antibiotics.
Submerged fermentation in large steel tanks, developed under wartime pressure, turned penicillin from a scarce laboratory extract into a mass-produced drug, establishing industrial fermentation methods still used for antibiotics.
Kyowa Hakko scientists isolated Corynebacterium glutamicum, enabling low-cost microbial production of glutamate and later lysine, and establishing Japan as a founder of the modern industrial fermentation industry.
The cell line isolated at the University of Colorado became the standard host for manufacturing complex biologic drugs, and CHO cells are still used to produce most therapeutic antibodies today.
Splicing foreign DNA into bacteria and having it replicate gave biomanufacturing its foundational tool, turning microorganisms into programmable production hosts for proteins they do not naturally make.
Fusing antibody-producing cells with myeloma cells created a way to manufacture a single, uniform antibody indefinitely, the basis of the monoclonal antibody industry that now dominates biologic drug sales.
Humulin, human insulin manufactured by genetically engineered bacteria, replaced insulin extracted from animal pancreases and proved that engineered microorganisms could manufacture a protein drug at commercial scale.
State-linked and private manufacturers built vast fermentation capacity for penicillin, vitamin and amino acid intermediates, making China the dominant global supplier of bulk pharmaceutical ingredients still relied on today.
NCBioImpact was set up in 2004 as a comprehensive state-wide training network for biomanufacturing skills. Such workforce initiatives matter because biomanufacturing depends on personnel trained in the specialised equipment and cell-culture techniques used to grow microbes, animal cells and plant cells.
Pfizer-BioNTech and Moderna took lipid-nanoparticle mRNA production from laboratory scale to billions of doses within a year, establishing a manufacturing platform now being adapted for other diseases.
Proposals discussed at the Communist Party's autumn plenum set biomanufacturing alongside other frontier sectors as a priority for the 2026 to 2030 planning period, continuing state support for fermentation and cell-culture capacity.
Plant 5 at the company's Songdo bio campus added large-scale mammalian cell-culture capacity, reinforcing South Korea's position as host to the world's biggest contract biologics manufacturer by volume.
Brazil's Bio-Manguinhos institute, using technology licensed through the WHO mRNA hub network, produced its first batches of locally made mRNA vaccine antigen, part of a wider Latin American push for manufacturing independence.
The Cape Town firm, hub of the WHO-backed mRNA technology transfer programme, moved its reverse-engineered COVID-19 vaccine candidate into a Phase 1 trial, a step toward African vaccine manufacturing self-sufficiency.
Facing possible exclusion from US federal contracts under proposed legislation, the contract manufacturer continued building capacity in Singapore and Ireland to keep serving Western customers from outside mainland China.
Completion of Novo Holdings' acquisition of Catalent transferred sterile fill-finish sites to Novo Nordisk, adding capacity dedicated to easing the shortage of injectable GLP-1 weight-loss and diabetes drugs.
The bill would bar federal agencies from contracting with named Chinese biomanufacturers, including WuXi Biologics and WuXi AppTec, citing national security concerns over reliance on Chinese-made biologics.
The Cabinet-approved Biotechnology for Economy, Environment and Employment policy set out support for bio-based chemicals, bioplastics and biopharmaceuticals, aiming to build regional biomanufacturing hubs and cut import dependence.
The synthetic biology and foundry company restructured as pandemic-era biosecurity revenue fell away, narrowing its focus toward cell engineering services and away from broader platform ambitions.
The state became the first in the US to prohibit sale of lab-grown meat outright, a move other states followed, complicating the commercial path for cultivated-protein biomanufacturers.